Fobi Incorporates And Launches New Wholly Owned Subsidiary PulseIR

Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer and investor activation and engagement, announces the launch of its wholly owned subsidiary PulseIR. PulseIR will not only provide a new data driven and mobile approach to Investor Relations with Fobi’s recently launched Investor Pass […]

Continue Reading

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today new milestones in potential therapeutic approaches for ALS.   Almost all cases of ALS, and about half of cases of […]

Continue Reading

LamontCo Announces Matthew Ronk as Senior Director with Lamont Associates

Hospitality leader, Matthew Ronk, brings industry expertise and dynamic experience to growing team at Lamont Associates.   LamontCo announces Matthew Ronk will join the growing team at Lamont Associates as Senior Director. As a hospitality leader, Matthew joins the Lamont Associates team with nearly 24 years in the industry.   As a veteran of the hospitality industry, […]

Continue Reading

Fobi Launches Verified Digital and First of its Kind App-less Investor Relations Platform Leveraging Fobi’s AI, Big Data and Mobile Wallet Technology

Investor Pass utilizes Fobi’s Wallet pass platform for IR communications to unify all the touchpoints that companies have with their investors to deliver personalized information in real-time to their shareholders.   Fobi Launches Verified Digital and First of its Kind App-less Investor Relations Platform Leveraging Fobi’s AI, Big Data and Mobile Wallet Technology   Investor […]

Continue Reading

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer.   Brings decades of experience in Alzheimer’s research […]

Continue Reading

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.   NemaLife will evaluate the efficacy of these compounds using its high-throughput C. elegans-based in vivo screening platform. This high-throughput […]

Continue Reading

Skyharbour’s Partner Company Basin Uranium Corp. Announces Completion and Mobilization of Exploration Crews to Mann Lake Uranium Project

Skyharbour Resources Ltd.’s (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) partner company, Basin Uranium Corp. (“Basin Uranium”), is pleased to announce its exploration plan for its Phase 1 program at the Mann Lake uranium project in Saskatchewan’s prolific Athabasca Basin.   The Mann Lake project is located 25 km southwest of the McArthur River Mine, the largest high-grade uranium deposit in […]

Continue Reading

Freedom to Operate Publishes Open Letter to Compass Pathways Challenging Validity of Psilocybin Patent

The non-profit, Freedom to Operate (FTO), has just published an open letter to Compass Pathways’ CEO, George Goldsmith, regarding the invalidity of one of Compass’ U.S. patents on psilocybin.   Letter Serves to Put Compass on Notice Regarding Invalidity of U.S. Patent No. 11,149,044   The letter, which marks the fifth occasion on which FTO has disputed the validity […]

Continue Reading